Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/30/2003WO2002042284A1 Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives
05/30/2003WO2002041897A3 Novel pharmaceutical compositions with anti-diabetic activity and method for preparing same
05/30/2003WO2002036116A9 Tripeptidyl peptidase inhibitors
05/30/2003WO2002020090A3 Pharmaceutical compositions
05/30/2003WO2002016313A3 Integrin receptor inhibitors
05/30/2003WO2001080823A3 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
05/30/2003CA2506616A1 Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients
05/30/2003CA2492536A1 Postsynaptic proteins
05/30/2003CA2468170A1 Method for identification of tumor targeting enzymes
05/30/2003CA2468046A1 Novel tetronic acid derivative
05/30/2003CA2467930A1 Treatment of pml targeting jc virus agno
05/30/2003CA2467915A1 Compositions inhibiting rejection in organ transplantation and method of using the same
05/30/2003CA2467908A1 Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages
05/30/2003CA2467749A1 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467557A1 Agent which mobilizes multipotential stem cells from tissues to peripheral blood
05/30/2003CA2467551A1 Benzothiazole derivatives as adenosine receptor ligands
05/30/2003CA2467476A1 Amino diols useful in the treatment of alzheimer's disease
05/30/2003CA2467223A1 Method for extending the useful shelf-life of refrigerated red blood cells by nutrient supplementation
05/30/2003CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003CA2467166A1 New pharmaceutical compounds
05/30/2003CA2467104A1 A plant extract active as an immunostimulating agent
05/30/2003CA2466916A1 New use for the treatment of gastroesophageal reflux disease
05/30/2003CA2466733A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003CA2429539A1 Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives
05/29/2003US20030100942 Hydrogel for the therapeutic treatment of aneurysms
05/29/2003US20030100772 Oxygen-containing heterocyclic compounds
05/29/2003US20030100770 D-proline derivatives
05/29/2003US20030100769 Such s 2-(6-chloro-3-pyridyl)-2-imidazoline which has good affinity for and activate alpha-4-beta-2-nicotinic acetyl-choline receptors; for treatment and prevention of neuro-degenerative disorders (Alzheimer's/Parkinson's disease)
05/29/2003US20030100755 For example (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl)amino-1,6-diphenylhexane; HIV therapy
05/29/2003US20030100608 1,4-disubstituted benzo-fused cycloalkyl urea compounds
05/29/2003US20030100607 Thiolalkyl benzoic acid derivatives
05/29/2003US20030100603 Administering to the patient subject to a C-reactive protein associated inflammatory condition, an effective amount of a non-alpha-tocopherol enriched tocopherol
05/29/2003US20030100599 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands
05/29/2003US20030100596 Arylsulphonyl substituted-tetrahydro- and hexahydro-carbazoles
05/29/2003US20030100595 Oral dosage form of a sulfonamide prodrug
05/29/2003US20030100594 Carbonic anhydrase inhibitor
05/29/2003US20030100588 Indole-type inhibitors of p38 kinase
05/29/2003US20030100577 Neurotrophic agents in treatment of solid tumors and vascular disease
05/29/2003US20030100571 Such as 2-((6-(((4-(3,4-dimethoxyphenyl)methyl)amino)-7-ethyl-7H-purin-2-yl)amino) -4,5-methyl-N-phenyl-5-thiazole-carboxamide for treatment of lymphocyte mediated diseases such as transplant rejection and graft versus host disease
05/29/2003US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors
05/29/2003US20030100567 Tyrosine kinase inhibitors
05/29/2003US20030100563 Such as 7-((3R)-3-amino-4-(3,4-difluorophenyl)butanoyl)-2-(trifluoromethyl)-5,6,7,8 -tetrahydroimidazo(1,2-a)pyrazine dihydrochloride for treatment of insulin resistance disorders
05/29/2003US20030100561 Treatment of insulin resistance with growth hormone secretagogues
05/29/2003US20030100553 Farnesyl protein transferase inhibitor combinations with camptothecin compounds
05/29/2003US20030100551 Production of apoptotic films for direct contact with tumors
05/29/2003US20030100548 Antiarthritic agents; atherosclerosis and chronic obstructive pulmonary disease treatments
05/29/2003US20030100545 Psychological disorder treatments that increase the activity of cholinergic receptors
05/29/2003US20030100542 5-hydroxysapogenin derivatives with anti-dementia activity
05/29/2003US20030100539 Metabotropic glutamate receptors (mGluR); treating fragile X, autism, mental retardation, schizophrenia and Down's Syndrome
05/29/2003US20030100536 Treating a herpes virus, atherosclerosis or restenosis
05/29/2003US20030100525 Amino acid sequences; anticaner agents, monitoring, diagnosis
05/29/2003US20030100518 13-Methyl erythromycin derivatives
05/29/2003US20030100517 For therapy of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g.skin plays a role
05/29/2003US20030100510 Crystallized structure of type IV collagen NC1 domain hexamer
05/29/2003US20030100507 Administering to a mammal therapeutically effective amount of opiate analgesic and endothelin antagonist for therapy and prophylaxis of pain
05/29/2003US20030100484 Cell in which a urotensin II receptor is formed is contacted with a chemical compound; activity or quantity of a gene, or its gene product, from the cell from is determined, comparing with gene product of control cell
05/29/2003US20030100478 Articles of manufacture
05/29/2003US20030100083 Preparation of pseudomonic acid A; obtain bacteria capable of producing pseudomonic acid A, culture, ferment and isolate pseudomonic acid A from culture
05/29/2003US20030100034 Detection of modulators of cell activity; obtain cell, incubate with modulator, measure the concentration of target polypeptide, evaluate for cancer
05/29/2003US20030100026 Stimulus-inducible protein kinase complex and methods of use therefor
05/29/2003US20030100018 Mass-based encoding and qualitative analysis of combinatorial libraries
05/29/2003US20030100017 Prevention of microorganismal infections; obtain sample of microorganism, incubate with tetracycline compound, monitor propagation of microorganism, reduced propagation indicates effective fungicide
05/29/2003US20030099971 Epidermal differentiation factor
05/29/2003US20030099718 Nanocrystalline antimicrobial metals (noble metals)formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal sufficient to cause microbiocidal effect; anti-inflammatory activity
05/29/2003US20030099700 Orodispersible tablets, able to disintegrate in buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 seconds, containing fexofenadine or its salt in the form of a coated granule, and excipients
05/29/2003US20030099660 For regenerating tissues; antiaging agents; medical diagnosis; monitoring chemotherapy
05/29/2003US20030099654 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss
05/29/2003US20030099653 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
05/29/2003US20030099600 Metalloproteinase inhibitors for the treatment of respiratory diseases
05/28/2003EP1314741A1 Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof
05/28/2003EP1314733A1 Indole-2-carboxamides as factor Xa inhibitors
05/28/2003EP1314728A1 Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives
05/28/2003EP1314723A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/28/2003EP1314721A1 Novel propenohydroxamic acid derivatives
05/28/2003EP1314719A1 Benzoic acid derivatives and drugs containing the same as the active ingredient
05/28/2003EP1314426A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/28/2003EP1314425A1 Medicinal compositions for preventing or treating heart failure
05/28/2003EP1314423A1 Medicinal compositions
05/28/2003EP1313885A2 Methods of using agents that modulate bone formation and inhibit adipogenesis
05/28/2003EP1313874A1 Pharmaceutical compositions comprising a modulator of adamts-1
05/28/2003EP1313854A2 Transporters and ion channels
05/28/2003EP1313853A2 Modulation of fas and fasl expression
05/28/2003EP1313844A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313843A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
05/28/2003EP1313772A1 New cross-linked derivatives of hyaluronic acid
05/28/2003EP1313762A2 Suppressor gene
05/28/2003EP1313753A2 Regulator gene and system useful for the diagnosis and therapy of osteoporosis
05/28/2003EP1313740A1 Prodrugs of imidazopyridine derivatives
05/28/2003EP1313738A1 Process for the preparation and purification of thiol-containing maytansinoids
05/28/2003EP1313737A1 Novel guanidino derivatives as inhibitors of cell adhesion
05/28/2003EP1313734A2 Aza heterocyclic derivatives and their therapeutic use
05/28/2003EP1313733A1 Pyrazolopyridine compound and pharmaceutical use thereof
05/28/2003EP1313732A1 Oxindole derivatives
05/28/2003EP1313730A1 Pyrrolidine derivatives and their use as chymase inhibitor
05/28/2003EP1313728A1 Substituted pyrimidines as selective cyclooxygenase-2 inhibitors
05/28/2003EP1313726A1 Quinoline derivatives having vegf inhibiting activity
05/28/2003EP1313725A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
05/28/2003EP1313721A2 Non-imidazole aryloxyalkylamines as h3 receptor ligands
1 ... 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 ... 1564